Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-na

Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-na(i)ve Patients Infected with Genotype 1b

Hepatitis C Virus

Ye Wang;Hui-Ying Rao;Xing-Wang Xie;Lai Wei

【期刊名称】《中华医学杂志（英文版）》 【年(卷),期】2015(128)019

【摘要】Background:It has been reported that several baseline polymorphisms of direct-acting antivirals (DAAs) agents resistance-associated variants (RAVs) would affect the treatment outcomes of patients chronically infected with hepatitis C virus (CHC).The aim of this study is to investigate the prevalence of DAAs RAVs in treatment-na(i)ve GT1b CHC patients.Methods:Direct sequencing and ultra-deep sequencing of the HCV NS3,NS5A,and NS5B gene were performed in baseline serum samples of treatment-ha(i)ve patients infected with genotype lb hepatitis C virus (HCVs).Results:One hundred and sixty CHC patients were studied.Complete sequence information was obtained for 145

patients

(NS3),148

patients

(NS5A),and

137

patients

(NS5B).Treatment-failure associated variants of DAAs were detected:56.6％ (82/145) of the patients presented S122G for simeprevir (NS3 protease inhibitor);10.1％ (14/148) of the patients presented Y93H for daclatasvir and ledipasvir (NS5A protein inhibitors);94.2％ (129/137) of the patients